SCHEMBL4090714

SCHEMBL4090714

NC(Cc1ccccc1)c1nc(-c2ccc(F)cc2F)nc2ccccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ PRKCI P41743 2/20 0.38
▸ HIF1A Q16665 1/20 0.37
▸ APP P05067 2/20 0.36
▸ ACHE P22303 1/20 0.36
▸ MEN1 O00255 4/20 0.36
▸ KMT2A Q03164 4/20 0.36
▸ GBA1 P04062 1/20 0.36
▸ LMNA P02545 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ USP1 O94782 1/20 0.35
▸ WDR48 Q8TAF3 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ CHEK2 O96017 1/20 0.35
▸ GRM2 Q14416 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14529444 0.75 ACHE (0.49) MAPTMAPK1POLBHIF1AAPP
SCHEMBL4753567 0.75 MAPT (0.41) MAPTMAPK1POLBHIF1AACHE
SCHEMBL4090716 0.72 MAPT (0.51) MAPTMAPK1POLBAPPMEN1
SCHEMBL4090718 0.71 PDE5A (0.63) MAPTPOLBGBA1LMNASMN1; SMN2
SCHEMBL16038390 0.70 SMN1; SMN2 (0.45) MAPTHIF1AACHEMEN1KMT2A
SCHEMBL1083778 0.69 CYP2D6 (0.63) MAPTMAPK1HIF1AMEN1KMT2A
SCHEMBL4753568 0.69 CYP1A2 (0.63) MAPTMAPK1POLBMEN1KMT2A
SCHEMBL5785783 0.69 ADORA2A (0.45) ACHEGRM2CYP1A2CYP3A4CYP2D6
SCHEMBL4090989 0.68 HIF1A (0.76) MAPTMAPK1HIF1AMEN1KMT2A
SCHEMBL15452624 0.67 ABCG2 (0.65) MAPTMAPK1GBA1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 MAPT 4125/4885MAPK1 2435/4885POLB 4057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback